Table. Minimum inhibitory concentrations of 15 antimicrobial drugs for the ceftriaxone-resistant, multidrug-resistant Neisseria gonorrhoeae F92 isolate, France, June 2022.
| Antimicrobial drug | MIC in mg/L | Interpretation (EUCAST v 12.0 [1]) |
|---|---|---|
| Ceftriaxone | 0.5 | Resistant |
| Cefixime | 2 | Resistant |
| Cefotaxime | 2 | Resistant |
| Cefoxitin | 2 | Resistant |
| Benzylpenicillin | 2 | Resistant |
| Ciprofloxacin | > 32 | Resistant |
| Tetracycline | 4 | Resistant |
| Azithromycin | 0.5 | Susceptible |
| Spectinomycin | 16 | Susceptible |
| Gentamicin | 8 | NA (Wild-type MIC) |
| Rifampicin | 0.5 | NA (Wild-type MIC) |
| Ertapenem | 0.032 | NA (Wild-type MIC) |
| Zoliflodacina | 0.064 | NA (Wild-type MIC) |
| Gepotidacina | 0.25 | NA (Wild-type MIC) |
| Lefamulinb | 0.5 | NA (Wild-type MIC) |
EUCAST: European Committee on Antimicrobial Susceptibility Testing; MIC: minimum inhibitory concentration; NA: not applicable (because of lack of breakpoints for interpretation).
a Pre-licensing international phase III randomised clinical trials underway [2,3].
b Novel antimicrobial that has shown promising results in MIC testing [4].
Antimicrobial MIC in mg/L interpretation (EUCAST v 12.0 [1]). Wild-type MIC is the MIC usually observed for Neisseria gonorrhoeae not resistant to the antibiotic tested.